Team receives $2.7M to develop new treatment options
Glioblastoma is the deadliest and most common type of brain tumor, killing 15,000 Americans each year. Because the tumors are resistant to current treatments, there is an urgent need to develop new options for patients with the disease. A research team led by Jeremy Rich, MD, Chair of the Department of Stem Cell Biology and Regenerative Medicine, will study the effects of disrupting the tumor cells' ability to metabolize iron, an essential cellular process. Preliminary work has shown that blocking this pathway makes tumors more sensitive to chemotherapy. Dr. Rich and his collaborator, James R. Connor, PhD, of Pennsylvania State University, received $2.7M from the National Cancer Institute to further these studies, combining their expertise in iron biology, drug delivery and cancer and examining this potential new therapeutic approach.